Aromatase Antibody (Rabbit mAb) [D20L3]

Application: Reactivity: Human

Usage Information

Dilution
WB1:500 - 1:5000 IHC1:50 - 1:200 IF1:20 - 1:200

Application
WB, IHC, IF

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
58 kDa 58 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Aromatase Antibody (Rabbit mAb) [D20L3] detects endogenous levels of total Aromatase protein.

Clone
D20L3

Synonym(s)
ARO1, CYAR, CYP19, CYP19A1, Aromatase, CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, Estrogen synthase

Background
Aromatase, encoded by CYP19A1, is a microsomal cytochrome P450 monooxygenase that catalyzes the terminal step of estrogen biosynthesis by converting C19 androgens such as testosterone and androstenedione into phenolic C18 estrogens, positioning it as a key enzymatic node in steroidogenesis and estrogen signaling across reproductive and non‑reproductive tissues. The protein belongs to the broader P450 family yet exhibits a highly specialized active site architecture that supports sequential hydroxylation and oxidative C19 demethylation, culminating in aromatization of the A‑ring; its membrane‑bound topology and association with NADPH–P450 reductase form the core catalytic unit that channels electrons for this multi‑step reaction. Mechanistically, aromatase performs three consecutive monooxygenase reactions on the C19 methyl group located between the A and B rings of the androgen substrate, generating hydroxylated intermediates and an aldehyde before cleaving the C19 carbon as formic acid and simultaneously rearranging the A‑ring to an aromatic structure, while converting the C3 carbonyl to a hydroxyl group and introducing a double bond at C2–C3 to yield estrone, which can then be reduced to estradiol. This enzymatic sequence defines the rate‑limiting step for local estrogen production in tissues such as adipose tissue, breast, endometrium, ovary and brain, where aromatase expression provides site‑specific control over estrogen availability that feeds into nuclear estrogen receptor pathways regulating gene transcription involved in proliferation, differentiation and metabolic homeostasis. Tissue‑selective expression of CYP19A1 is driven by at least ten alternative promoters that respond to distinct signaling inputs; glucocorticoid‑responsive promoter I.4 predominates in subcutaneous adipose tissue under physiological conditions, whereas cAMP‑responsive promoters I.3 and II are activated in peritumoral fibroblasts of hormone‑dependent breast cancers, shifting aromatase expression to the tumor microenvironment and increasing local estrogen formation. In hormone receptor‑positive breast cancer, aromatase activity is frequently elevated in tumor epithelial cells and surrounding stromal adipose tissue, generating estrogen concentrations in the breast that can match or exceed those in premenopausal plasma and driving autocrine and paracrine stimulation of estrogen receptor–positive tumor growth. Measurements of aromatase activity and correlations with proliferating cell nuclear antigen and thymidine incorporation in breast tumor histocultures show that tumors with higher aromatase activity respond more strongly to testosterone with increased DNA synthesis, indicating that locally synthesized estrogen from aromatase substrates contributes directly to proliferative signaling. Regulatory switches in promoter usage, together with cytokine and growth factor inputs, enhance aromatase expression specifically in malignant breast tissue and in fibroblasts adjacent to cancer cells, establishing a microenvironment in which CYP19A1‑mediated estrogen production is tightly linked to tumor progression and provides a defined molecular target for inhibitor therapy. Germline loss‑of‑function mutations in CYP19A1 cause aromatase deficiency, characterized by low estrogen and elevated androgen levels and leading to disordered sex development, impaired secondary sexual maturation, tall stature with delayed bone age, osteoporosis and metabolic disturbances, illustrating the systemic reliance on aromatase‑generated estrogens for skeletal, metabolic and reproductive physiology.

Background

Aromatase, encoded by CYP19A1, is a microsomal cytochrome P450 monooxygenase that catalyzes the terminal step of estrogen biosynthesis by converting C19 androgens such as testosterone and androstenedione into phenolic C18 estrogens, positioning it as a key enzymatic node in steroidogenesis and estrogen signaling across reproductive and non‑reproductive tissues. The protein belongs to the broader P450 family yet exhibits a highly specialized active site architecture that supports sequential hydroxylation and oxidative C19 demethylation, culminating in aromatization of the A‑ring; its membrane‑bound topology and association with NADPH–P450 reductase form the core catalytic unit that channels electrons for this multi‑step reaction. Mechanistically, aromatase performs three consecutive monooxygenase reactions on the C19 methyl group located between the A and B rings of the androgen substrate, generating hydroxylated intermediates and an aldehyde before cleaving the C19 carbon as formic acid and simultaneously rearranging the A‑ring to an aromatic structure, while converting the C3 carbonyl to a hydroxyl group and introducing a double bond at C2–C3 to yield estrone, which can then be reduced to estradiol. This enzymatic sequence defines the rate‑limiting step for local estrogen production in tissues such as adipose tissue, breast, endometrium, ovary and brain, where aromatase expression provides site‑specific control over estrogen availability that feeds into nuclear estrogen receptor pathways regulating gene transcription involved in proliferation, differentiation and metabolic homeostasis. Tissue‑selective expression of CYP19A1 is driven by at least ten alternative promoters that respond to distinct signaling inputs; glucocorticoid‑responsive promoter I.4 predominates in subcutaneous adipose tissue under physiological conditions, whereas cAMP‑responsive promoters I.3 and II are activated in peritumoral fibroblasts of hormone‑dependent breast cancers, shifting aromatase expression to the tumor microenvironment and increasing local estrogen formation. In hormone receptor‑positive breast cancer, aromatase activity is frequently elevated in tumor epithelial cells and surrounding stromal adipose tissue, generating estrogen concentrations in the breast that can match or exceed those in premenopausal plasma and driving autocrine and paracrine stimulation of estrogen receptor–positive tumor growth. Measurements of aromatase activity and correlations with proliferating cell nuclear antigen and thymidine incorporation in breast tumor histocultures show that tumors with higher aromatase activity respond more strongly to testosterone with increased DNA synthesis, indicating that locally synthesized estrogen from aromatase substrates contributes directly to proliferative signaling. Regulatory switches in promoter usage, together with cytokine and growth factor inputs, enhance aromatase expression specifically in malignant breast tissue and in fibroblasts adjacent to cancer cells, establishing a microenvironment in which CYP19A1‑mediated estrogen production is tightly linked to tumor progression and provides a defined molecular target for inhibitor therapy. Germline loss‑of‑function mutations in CYP19A1 cause aromatase deficiency, characterized by low estrogen and elevated androgen levels and leading to disordered sex development, impaired secondary sexual maturation, tall stature with delayed bone age, osteoporosis and metabolic disturbances, illustrating the systemic reliance on aromatase‑generated estrogens for skeletal, metabolic and reproductive physiology.

References
https://pubmed.ncbi.nlm.nih.gov/27067638/ https://pubmed.ncbi.nlm.nih.gov/27252161/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%